JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1988; 11:1118-1123
© 1988 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, W.
Right arrow Articles by Katz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, W.
Right arrow Articles by Katz, A.

Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam

WB White, MJ Radford, FM Gonzalez, SG Weed, EJ McCabe, and AM Katz

Department of Medicine, University of Connecticut School of Medicine, Farmington.

To determine the effects of dopamine-1 agonist therapy in severe hypertension, blood pressure, heart rate, catecholamines and left ventricular function were studied in 18 patients (10 with renal disease) with diastolic blood pressure greater than 120 mm Hg (range 124 to 160) after intravenous fenoldopam therapy. Constant infusions of fenoldopam were titrated upward every 10 to 20 min from an initial dose of 0.1 microgram/kg per min to a maximal dose of 0.9 microgram/kg per min. The therapeutic goal of a supine diastolic blood pressure of less than 110 mm Hg was achieved in every patient within 1 h at an average dose of 0.34 +/- 0.22 microgram/kg per min. Blood pressure decreased from 214/134 +/- 33/10 mm Hg at baseline to 170/96 +/- 29/7 mm Hg (p less than 0.0001) at 3 h, whereas heart rate increased from 77 +/- 23 to 88 +/- 21 beats/min (p less than 0.01). Plasma norepinephrine increased during the fenoldopam infusion; epinephrine and dopamine levels did not change. Two indexes of left ventricular function (end-systolic dimension and isovolumic relaxation time) improved during the fenoldopam infusion, but mitral flow velocities during ventricular filling were unchanged. Side effects of intravenous fenoldopam were mild, transient and associated with the marked vasodilatory properties of the drug. Thus, fenoldopam is safe and effective as a parenteral monotherapy in patients with severe essential and renovascular hypertension. Preliminary data suggest that blood pressure reduction with selective dopamine-1 agonist therapy is accompanied by improved left ventricular function.


This article has been cited by other articles:


Home page
 ChestHome page
P. E. Marik and J. Varon
Hypertensive Crises: Challenges and Management
Chest, June 1, 2007; 131(6): 1949 - 1962.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
W. C. Oliver Jr, G. A. Nuttall, K. J. Cherry, P. A. Decker, T. Bower, and M. H. Ereth
A Comparison of Fenoldopam with Dopamine and Sodium Nitroprusside in Patients Undergoing Cross-Clamping of the Abdominal Aorta
Anesth. Analg., October 1, 2006; 103(4): 833 - 840.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
T. B. Gilbert, J. U. Hasnain, W. R. Flinn, M. P. Lilly, and M. E. Benjamin
Fenoldopam Infusion Associated with Preserving Renal Function After Aortic Cross-Clamping for Aneurysm Repair
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 31 - 36.
[Abstract] [PDF]

Home page
 ChestHome page
J. Varon and P. E. Marik
The Diagnosis and Management of Hypertensive Crises
Chest, July 1, 2000; 118(1): 214 - 227.
[Abstract] [Full Text] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1988 by the American College of Cardiology Foundation.